Identification of pyruvate kinase in methicillin-resistant Staphylococcus aureus as a novel antimicrobial drug target

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2042-2053

  Zoraghi, Roya ^a   See, Raymond H ^a   Axerio Cilies, Peter ^a   Kumar, Nag S ^b   Gong, Huansheng ^a   Moreau, Anne ^b   Hsing, Michael ^a,c   Kaur, Sukhbir ^a   Swayze, Richard D ^a   Worrall, Liam ^a   Amandoron, Emily ^a   Lian, Tian ^a   Jackson, Linda ^a   Jiang, Jihong ^a   Thorson, Lisa ^a   Labriere, Christophe ^b   Foster, Leonard ^a   Brunham, Robert C ^a   McMaster, William R ^a   Finlay, B Brett ^a   Strynadka, Natalie C ^a   Cherkasov, Artem ^a,c   Young, Robert N ^b   Reiner, Neil E ^a   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AM 165; AM 168; ANTIBIOTIC AGENT; CIPROFLOXACIN; FUSIDIC ACID; IS 130; IS 63; NSK 4 66; NSK 4 77; NSK 5 15; PHOSPHOTRANSFERASE INHIBITOR; PYRUVATE KINASE; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENZYME ACTIVITY; ENZYME INHIBITION; ESCHERICHIA COLI; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; SEQUENCE ALIGNMENT; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS SAPROPHYTICUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; VANCOMYCIN RESISTANT ENTEROCOCCUS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; PYRUVATE KINASE; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 79955533411     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01250-10     Document Type: Article

References (44)

1. Akerley, B. J., et al. 2002. A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proc. Natl. Acad. Sci. U. S. A. 99:966-971.
2. Alanis, A. J. 2005. Resistance to antibiotics: are we in the post-antibiotic era? Arch. Med. Res. 36:697-705.
3. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410.
4. Baranowska, B., and T. Baranowski. 1982. Kinetic properties of human muscle pyruvate kinase. Mol. Cell. Biochem. 45:117-125.
5. Barrett, C. T., and J. F. Barrett. 2003. Antibacterials: are the new entries enough to deal with the emerging resistance problems? Curr. Opin. Biotechnol. 14:621-626.
6. Chan, M., D. S. Tan, and T. S. Sim. 2007. Plasmodium falciparum pyruvate kinase as a novel target for antimalarial drug-screening. Travel Med. Infect. Dis. 5:125-131.
7. Cherkasov, A., et al. 2011. Mapping the protein interaction network in methicillin-resistant Staphylococcus aureus. J. Proteome Res. 10:1139-1150. [Epub ahead of print.]
8. Christofk, H. R., et al. 2008. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230-233. (Pubitemid 351380249)
9. Christofk, H. R., M. G. Vander Heiden, N. Wu, J. M. Asara, and L. C. Cantley. 2008. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452:181-186.
10. Collins, R. A., S. M. Kelly, N. C. Price, L. A. Fothergill-Gilmore, and H. Muirhead. 1996. Ligand-induced conformational changes in wild-type and mutant yeast pyruvate kinase. Protein Eng. 9:1203-1210.
11. Cunningham, D. S., et al. 2009. Pyruvate kinase-deficient Escherichia coli exhibits increased plasmid copy number and cyclic AMP levels. J. Bacteriol. 191:3041-3049.
12. Fraser, H. B., A. E. Hirsh, L. M. Steinmetz, C. Scharfe, and M. W. Feldman. 2002. Evolutionary rate in the protein interaction network. Science 296:750-752.
13. Hannaert, V., et al. 2002. The putative effector-binding site of Leishmania mexicana pyruvate kinase studied by site-directed mutagenesis. FEBS Lett. 514:255-259. (Pubitemid 34273949)
14. Ikeda, Y., T. Tanaka, and T. Noguchi. 1997. Conversion of non-allosteric pyruvate kinase isozyme into an allosteric enzyme by a single amino acid substitution. J. Biol. Chem. 272:20495-20501.
15. Irwin, J. J., and B. K. Shoichet. 2005. ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45:177-182.
16. Jurica, M. S., et al. 1998. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure 6:195-210. (Pubitemid 28153883)
17. Kharalkar, S. S., et al. 2007. Identification of novel allosteric regulators of human-erythrocyte pyruvate kinase. Chem. Biodivers. 4:2603-2617.
18. Larsen, T. M., L. T. Laughlin, H. M. Holden, I. Rayment, and G. H. Reed. 1994. Structure of rabbit muscle pyruvate kinase complexed with Mn2+, K+, and pyruvate. Biochemistry 33:6301-6309.
19. Marshall, N. J., C. J. Goodwin, and S. J. Holt. 1995. A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function. Growth Regul. 5:69-84.
20. Mattevi, A., et al. 1995. Crystal structure of Escherichia coli pyruvate kinase type I: molecular basis of the allosteric transition. Structure 3:729-741.
21. Monroe, S., and R. Polk. 2000. Antimicrobial use and bacterial resistance. Curr. Opin. Microbiol. 3:496-501.
22. Morgan, H. P., et al. 2010. The allosteric mechanism of pyruvate kinase from Leishmania mexicana: a rock and lock model. J. Biol. Chem. 285:12892-12898.
23. Munoz, M. E., and E. Ponce. 2003. Pyruvate kinase: current status of regulatory and functional properties. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 135:197-218.
24. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
25. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
26. Nowicki, M. W., et al. 2008. Design, synthesis and trypanocidal activity of lead compounds based on inhibitors of parasite glycolysis. Bioorg. Med. Chem. 16:5050-5061.
27. Opperdoes, F. R., and P. A. Michels. 2001. Enzymes of carbohydrate metabolism as potential drug targets. Int. J. Parasitol. 31:482-490.
28. Pathania, R., and E. D. Brown. 2008. Small and lethal: searching for new antibacterial compounds with novel modes of action. Biochem. Cell Biol. 86:111-115.
29. Rigden, D. J., S. E. Phillips, P. A. Michels, and L. A. Fothergill-Gilmore. 1999. The structure of pyruvate kinase from Leishmania mexicana reveals details of the allosteric transition and unusual effector specificity. J. Mol. Biol. 291:615-635.
30. Rybak, M. J. 2004. Resistance to antimicrobial agents: an update. Pharmacotherapy 24:203S-215S.
31. Sassetti, C. M., D. H. Boyd, and E. J. Rubin. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48:77-84.
32. Silver, L. L., and K. A. Bostian. 1993. Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob. Agents Chemother. 37:377-383.
33. Somerville, G. A., et al. 2002. Staphylococcus aureus aconitase inactivation unexpectedly inhibits post-exponential-phase growth and enhances stationary-phase survival. Infect. Immun. 70:6373-6382.
34. Song, J. H., et al. 2005. Identification of essential genes in Streptococcus pneumoniae by allelic replacement mutagenesis. Mol. Cells 19:365-374.
35. Speranza, M. L., et al. 1989. Primary structure of three peptides at the catalytic and allosteric sites of the fructose-1,6-bisphosphate-activated pyruvate kinase from Escherichia coli. Biol. Chem. Hoppe Seyler 370:211-216.
36. Stuart, D. I., M. Levine, H. Muirhead, and D. K. Stammers. 1979. Crystal structure of cat muscle pyruvate kinase at a resolution of 2.6 A. J. Mol. Biol. 134:109-142.
37. Tulloch, L. B., et al. 2008. Sulphate removal induces a major conformational change in Leishmania mexicana pyruvate kinase in the crystalline state. J. Mol. Biol. 383:615-626.
38. Valentini, G., et al. 2000. The allosteric regulation of pyruvate kinase. J. Biol. Chem. 275:18145-18152.
39. Vander Heiden, M. G., et al. 2010. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 79:1118-1124.
40. Wang, C., et al. 2001. Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia. Blood 98:3113-3120.
41. Wright, G. D. 2003. Mechanisms of resistance to antibiotics. Curr. Opin. Chem. Biol. 7:563-569.
42. Yoneyama, H., and R. Katsumata. 2006. Antibiotic resistance in bacteria and its future for novel antibiotic development. Biosci. Biotechnol. Biochem. 70:1060-1075.
43. Zhang, R., H. Y. Ou, and C. T. Zhang. 2004. DEG: a database of essential genes. Nucleic Acids Res. 32:D271-D272.
44. Zoraghi, R., et al. 2010. Functional analysis, overexpression, and kinetic characterization of pyruvate kinase from methicillin-resistant Staphylococcus aureus. Biochemistry 49:7733-7747.